Geïncludeerd in de RATE-study

Antistollingstarget tijdens ECMO:

- **<u>1.5-2.0x baseline aPTT (45-60 seconden)</u>**

Voor crossover flowchart z.o.z.


Start ECMO
Start heparin
(may be postponed, e.g. in bleeding post-cardiac surgery patient)
Enrolment and randomization
LMWH
Therapeutic dose guided by weight and renal function
2-2.5x baseline aPTT (about 60-75 sec)
1.5-2.0x baseline aPTT (about 45-60 sec)
Anti-fXa peak level
(not mandatory)
>1.0 (twice daily dosing)
Severe bleeding or thromboembolic event (primary endpoint met)
Thromboembolic event (primary endpoint met) or acquired vital indication for high therapeutic anticoagulation
Or:
Bleeding requiring 1-3 PRBC/day and additional laboratory results that point towards a strong risk for
Or:
Bleeding requiring 1-3 PRBC/day and additional laboratory results that point towards a strong risk
Or:
≥2 ECMO exchanges due to clots and additional laboratory results that point towards a strong risk for hy-
Temporary withhold LMWH or reduce LMWH dose or switch temporary to heparin
Switch temporary to lower anticoagulation level or temporary withhold heparin
Switch temporary to higher anticoagulation level or LMWH